Mirtazapine Teva

Mirtazapine, the active ingredient in Mirtazapine Teva, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It treats major depressive disorder in adult patients. GNH USA supplies Mirtazapine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine Teva belongs to the NaSSA class and is indicated for depressive disorders. - Major depressive disorder: reduces depressive symptoms and improves mood in adults.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Somnolence

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Leukopenia - Hypersensitivity reactions such as rash or angioedema - Suicidal thoughts or behavior, especially early in treatment - Seizures

Before prescribing Mirtazapine Teva, clinicians should consider several safety aspects. - Hepatic impairment: dose may need adjustment - Monitor weight and metabolic parameters regularly - Caution in patients with a history of bipolar disorder or mania - Avoid abrupt discontinuation to reduce withdrawal symptoms - Pregnancy and lactation: risk unknown, use only if benefit outweighs potential harm - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Mirtazapine Teva can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis - Central nervous system depressants (alcohol, benzodiazepines): enhanced sedation - Strong CYP2D6 inhibitors (e.g., fluoxetine): increased plasma concentrations

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine): reduced efficacy - Anticholinergic agents: additive dry mouth - Other serotonergic drugs (SSRIs, SNRIs, tramadol): potential serotonin syndrome